Oncogenic mutant forms of EGFR: Lessons in signal transduction and targets for cancer therapy

FEBS Letters

Volumn 584, Issue 12, 2010, Pages 2699-2706

  Pines, Gur ^a   Köstler, Wolfgang J ^a   Yarden, Yosef ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

EGFR; ErbB; Glioblastoma; Kinase; Lung cancer; Mutations

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; CHAPERONE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 7; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; HEAT SHOCK PROTEIN 90; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; MUTANT PROTEIN; ONCOPROTEIN; PANITUMUMAB; PEPTIDE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOTRANSFERASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADVANCED CANCER; BREAST CANCER; CANCER RESISTANCE; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; PROTEIN VARIANT; REVIEW; SIGNAL TRANSDUCTION; WILD TYPE;

ANTIBODIES, MONOCLONAL; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MODELS, BIOLOGICAL; MUTATION; NEOPLASMS; ONCOGENES; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 77953133384     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2010.04.019     Document Type: Review

References (106)

1. Ushiro H., Cohen S. Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes. J. Biol. Chem. 1980, 255:8363-8365.
2. Cohen S., Carpenter G., King L. Epidermal growth factor-receptor-protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J. Biol. Chem. 1980, 255:4834-4842.
3. Ogiso H., et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002, 110:775-787.
4. Zhang X., Gureasko J., Shen K., Cole P.A., Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006, 125:1137-1149.
5. Citri A., Yarden Y. EGF-ErbB signalling: towards the systems level. Nat. Rev. Mol. Cell Biol. 2006, 7:505-516.
6. Yarden Y. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur. J. Cancer 2001, 37(Suppl. 4):S3-S8.
7. Casalini P., Iorio M.V., Galmozzi E., Menard S. Role of HER receptors family in development and differentiation. J. Cell. Physiol. 2004, 200:343-350.
8. Klapper L.N., Glathe S., Vaisman N., Hynes N.E., Andrews G.C., Sela M., Yarden Y. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc. Natl. Acad. Sci. USA 1999, 96:4995-5000.
9. Guy P.M., Platko J.V., Cantley L.C., Cerione R.A., Carraway K.L. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc. Natl. Acad. Sci. USA 1994, 91:8132-8136.
10. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2001, 2:127-137.
11. Ebner R., Derynck R. Epidermal growth factor and transforming growth factor-alpha: differential intracellular routing and processing of ligand-receptor complexes. Cell Regul. 1991, 2:599-612.
12. Sliwkowski M.X., et al. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J. Biol. Chem. 1994, 269:14661-14665.
13. Carraway K.L., Weber J.L., Unger M.J., Ledesma J., Yu N., Gassmann M., Lai C. Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases. Nature 1997, 387:512-516.
14. Harari D., Tzahar E., Romano J., Shelly M., Pierce J.H., Andrews G.C., Yarden Y. Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase. Oncogene 1999, 18:2681-2689.
15. Kochupurakkal B.S., et al. Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity. J. Biol. Chem. 2005, 280:8503-8512.
16. Normanno N., et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006, 366:2-16.
17. Barnes C.J., Kumar R. Epidermal growth factor receptor family tyrosine kinases as signal integrators and therapeutic targets. Cancer Metastasis Rev. 2003, 22:301-307.
18. Tang P., Steck P.A., Yung W.K. The autocrine loop of TGF-alpha/EGFR and brain tumors. J. Neurooncol. 1997, 35:303-314.
19. Downward J., et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 1984, 307:521-527.
20. Ekstrand A.J., Sugawa N., James C.D., Collins V.P. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc. Natl. Acad. Sci. USA 1992, 89:4309-4313.
21. Nagane M., Coufal F., Lin H., Bogler O., Cavenee W.K., Huang H.J. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res. 1996, 56:5079-5086.
22. Lee J.C., et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. 2006, 3:e485.
23. Gotoh N., Tojo A., Hino M., Yazaki Y., Shibuya M. A highly conserved tyrosine residue at codon 845 within the kinase domain is not required for the transforming activity of human epidermal growth factor receptor. Biochem. Biophys. Res. Commun. 1992, 186:768-774.
24. Lynch T.J., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350:2129-2139.
25. Nagahara H., et al. Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. Clin. Cancer Res. 2005, 11:1368-1371.
26. Douglas D.A., et al. Novel mutations of epidermal growth factor receptor in localized prostate cancer. Front. Biosci. 2006, 11:2518-2525.
27. Choi S.H., Mendrola J.M., Lemmon M.A. EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer. Oncogene 2007, 26:1567-1576.
28. Frederick L., Wang X.Y., Eley G., James C.D. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. 2000, 60:1383-1387.
29. Wood E.R., et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 2004, 64:6652-6659.
30. Jura N., et al. Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell 2009, 137:1293-1307.
31. Landau M., Fleishman S.J., Ben-Tal N. A putative mechanism for downregulation of the catalytic activity of the EGF receptor via direct contact between its kinase and C-terminal domains. Structure 2004, 12:2265-2275.
32. Ozer B.H., Wiepz G.J., Bertics P.J. Activity and cellular localization of an oncogenic glioblastoma multiforme-associated EGF receptor mutant possessing a duplicated kinase domain. Oncogene 2010, 29:855-864.
33. Sugawa N., Ekstrand A.J., James C.D., Collins V.P. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc. Natl. Acad. Sci. USA 1990, 87:8602-8606.
34. Wong A.J., Ruppert J.M., Bigner S.H., Grzeschik C.H., Humphrey P.A., Bigner D.S., Vogelstein B. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc. Natl. Acad. Sci. USA 1992, 89:2965-2969.
35. Moscatello D.K., et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 1995, 55:5536-5539.
36. Ji H., et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc. Natl. Acad. Sci. USA 2006, 103:7817-7822.
37. Wikstrand C.J., McLendon R.E., Friedman A.H., Bigner D.D. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res. 1997, 57:4130-4140.
38. Moscatello D.K., Montgomery R.B., Sundareshan P., McDanel H., Wong M.Y., Wong A.J. Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene 1996, 13:85-96.
39. Batra S.K., Castelino-Prabhu S., Wikstrand C.J., Zhu X., Humphrey P.A., Friedman H.S., Bigner D.D. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ. 1995, 6:1251-1259.
40. Al-Nedawi K., Meehan B., Micallef J., Lhotak V., May L., Guha A., Rak J. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat. Cell Biol. 2008, 10:619-624.
41. Sonobe M., Manabe T., Wada H., Tanaka F. Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. Br. J. Cancer 2005, 93:355-363.
42. Shigematsu H., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl. Cancer Inst. 2005, 97:339-346.
43. Shigematsu H., Gazdar A.F. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int. J. Cancer 2006, 118:257-262.
44. Landau M., Ben-Tal N. Dynamic equilibrium between multiple active and inactive conformations explains regulation and oncogenic mutations in ErbB receptors. Biochim. Biophys. Acta 2008, 1785:12-31.
45. Chen Y.R., Fu Y.N., Lin C.H., Yang S.T., Hu S.F., Chen Y.T., Tsai S.F., Huang S.F. Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants. Oncogene 2006, 25:1205-1215.
46. Moscatello D.K., Holgado-Madruga M., Emlet D.R., Montgomery R.B., Wong A.J. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J. Biol. Chem. 1998, 273:200-206.
47. Li B., Yuan M., Kim I.A., Chang C.M., Bernhard E.J., Shu H.K. Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin. Oncogene 2004, 23:4594-4602.
48. Huang P.H., Mukasa A., Bonavia R., Flynn R.A., Brewer Z.E., Cavenee W.K., Furnari F.B., White F.M. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc. Natl. Acad. Sci. USA 2007, 104:12867-12872.
49. Pedersen M.W., et al. Analysis of the epidermal growth factor receptor specific transcriptome: effect of receptor expression level and an activating mutation. J. Cell. Biochem. 2005, 96:412-427.
50. Shtiegman K., et al. Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling. Oncogene 2007, 26:6968-6978.
51. Cai C.Q., et al. Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations. Oncogene 2008, 27:3201-3210.
52. Carey K.D., et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res. 2006, 66:8163-8171.
53. Weinstein I.B. Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. Carcinogenesis 2000, 21:857-864.
54. Sharma S.V., Fischbach M.A., Haber D.A., Settleman J. " Oncogenic shock": explaining oncogene addiction through differential signal attenuation. Clin. Cancer Res. 2006, 12:4392s-4395s.
55. Levitzki A., Mishani E. Tyrphostins and other tyrosine kinase inhibitors. Annu. Rev. Biochem. 2006, 75:93-109.
56. Perez-Soler R. The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer. Clin. Cancer Res. 2004, 10:4238s-4240s.
57. Fukuoka M., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J. Clin. Oncol. 2003, 21:2237-2246.
58. Moore M.J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2007, 25:1960-1966.
59. Fountzilas G., et al. Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation. Cancer Invest. 2008, 26:784-793.
60. Geyer C.E., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 2006, 355:2733-2743.
61. Blackwell K.L., et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J. Clin. Oncol. 2010, 28:1124-1130.
62. Cobleigh M.A., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 1999, 17:2639-2648.
63. Slamon D.J., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344:783-792.
64. Romond E.H., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 2005, 353:1673-1684.
65. Piccart-Gebhart M.J., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 2005, 353:1659-1672.
66. Ben-Kasus T., Schechter B., Sela M., Yarden Y. Cancer therapeutic antibodies come of age: targeting minimal residual disease. Mol. Oncol. 2007, 1:42-54.
67. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 2000, 6:443-446.
68. Pirker R., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373:1525-1531.
69. Amado R.G., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008, 26:1626-1634.
70. Peeters M., Balfour J., Arnold D. Review article: panitumumab - a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer. Aliment. Pharmacol. Ther. 2008.
71. Scott A.M., et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc. Natl. Acad. Sci. USA 2007, 104:4071-4076.
72. Heimberger A.B., et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin. Cancer Res. 2003, 9:4247-4254.
73. Allen C., et al. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. Cancer Res. 2006, 66:11840-11850.
74. Yun C.H., Boggon T.J., Li Y., Woo M.S., Greulich H., Meyerson M., Eck M.J. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007, 11:217-227.
75. Kobayashi S., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2005, 352:786-792.
76. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., Kris M.G., Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005, 2:e73.
77. Bell D.W., et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat. Genet. 2005, 37:1315-1316.
78. Mellinghoff I.K., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 2005, 353:2012-2024.
79. Jhawer M., et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res. 2008, 68:1953-1961.
80. Lievre A., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006, 66:3992-3995.
81. Laurent-Puig P., et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J. Clin. Oncol. 2009, 27:5924-5930.
82. Kosaka T., Yatabe Y., Endoh H., Kuwano H., Takahashi T., Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 2004, 64:8919-8923.
83. Pearl L.H., Prodromou C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu. Rev. Biochem. 2006, 75:271-294.
84. Sangster T.A., Lindquist S., Queitsch C. Under cover: causes, effects and implications of Hsp90-mediated genetic capacitance. Bioessays 2004, 26:348-362.
85. Whitesell L., Mimnaugh E.G., De Costa B., Myers C.E., Neckers L.M. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA 1994, 91:8324-8328.
86. An W.G., Schulte T.W., Neckers L.M. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ. 2000, 11:355-360.
87. Zsebik B., Citri A., Isola J., Yarden Y., Szollosi J., Vereb G. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. Immunol. Lett. 2006, 104:146-155.
88. Shimamura T., Lowell A.M., Engelman J.A., Shapiro G.I. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res. 2005, 65:6401-6408.
89. Shimamura T., et al. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res. 2008, 68:5827-5838.
90. Lavictoire S.J., Parolin D.A., Klimowicz A.C., Kelly J.F., Lorimer I.A. Interaction of Hsp90 with the nascent form of the mutant epidermal growth factor receptor EGFRvIII. J. Biol. Chem. 2003, 278:5292-5299.
91. Yang S., Qu S., Perez-Tores M., Sawai A., Rosen N., Solit D.B., Arteaga C.L. Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors. Cancer Res. 2006, 66:6990-6997.
92. Biamonte M.A., Van de Water R., Arndt J.W., Scannevin R.H., Perret D., Lee W.C. Heat shock protein 90: inhibitors in clinical trials. J. Med. Chem. 2010, 53:3-17.
93. Nowell P.C. The clonal evolution of tumor cell populations. Science 1976, 194:23-28.
94. Merlo L.M., Pepper J.W., Reid B.J., Maley C.C. Cancer as an evolutionary and ecological process. Nat. Rev. Cancer 2006, 6:924-935.
95. Braakhuis B.J., Leemans C.R., Brakenhoff R.H. Expanding fields of genetically altered cells in head and neck squamous carcinogenesis. Semin. Cancer Biol. 2005, 15:113-120.
96. Zhou W., et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009, 462:1070-1074.
97. Sergina N.V., Rausch M., Wang D., Blair J., Hann B., Shokat K.M., Moasser M.M. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007, 445:437-441.
98. Engelman J.A., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ErbB3 signaling. Science 2007, 316:1039-1043.
99. Murphree A.L., Benedict W.F. Retinoblastoma: clues to human oncogenesis. Science 1984, 223:1028-1033.
100. Sheffer Y., et al. Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy-mediated antitumoral effect. Mol. Cancer Ther. 2007, 6:570-577.
101. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat. Rev. Drug Discov. 2007, 6:273-286.
102. Sekine I., et al. Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel. Ann. Oncol. 2009, 20:1483-1488.
103. Mok T.S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009, 361:947-957.
104. Humphrey P.A., et al. Deletion-mutant epidermal growth factor receptor in human gliomas: effects of type II mutation on receptor function. Biochem. Biophys. Res. Commun. 1991, 178:1413-1420.
105. Paez J.G., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
106. Greulich H., et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2005, 2:e313.